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Glucocorticoid administration before cardiopulmonary bypass (CPB) can reduce the systemic inflammatory response and improve
clinical outcome. Long pentraxin PTX3 is a novel inflammatory parameter that could play a protective cardiovascular role by
regulating inflammation. Twenty-nine children undergoing open heart surgery were enrolled in the study. Fourteen received
dexamethasone (1st dose 1.5mg/Kg i.v. or i.m. the evening before surgery; 2nd dose 1.5mg/kg i.v. before starting bypass) and
fifteen children served as control. Blood PTX3, short pentraxin C-reactive protein (CRP), interleukin-1 receptor II (IL-1RII),
fibrinogen and partial thromboplastin time (PTT) were assayed at diﬀerent times. PTX3 levels significantly increased during
CPB in dexamethasone-treated (+D) and dexamethasone-untreated (−D) subjects, but were significantly higher in +D than −D
patients. CRP levels significantly increased both in +D and −D patients in the postoperative days, with values significantly higher
in −D than +D patients. Fibrinogen and PTT values were significantly higher in −D than +D patients in the 1st postoperative
day. IL-1RII plasma levels increased in the postoperative period in both groups. Dexamethasone prophylaxis in pediatric patients
undergoing CPB for cardiac surgery is associated with a significant increase of blood PTX3 that could contribute to decreasing
inflammatory parameters and improving patient clinical outcome.
1. Introduction
Cardiopulmonary bypass (CPB) procedures during cardiac
surgery produce systemic eﬀects, especially in younger chil-
dren. The contact of cellular and humoral blood components
with biocompatible synthetic material of extracorporeal
circuit provokes a systemic inflammatory response (SIR)
involving leukocyte and endothelial cell activation and
cytokine release, which leads to myocardial, renal, and
pulmonary dysfunctions and has a negative impact on the
postoperative clinical course [1, 2].
Diﬀerent anti-inflammatory strategies have been used
to minimize the CPB-related organ dysfunctions, including
steroid prophylaxis with diﬀerent schedules of administra-
tion. Although glucocorticoid (GC) administration before
CPB has been found to result in a reduced inflammatory
response, the benefits of glucocorticoids on clinical outcome
of adult and pediatric patients are debated [3–9].
Pentraxins are a superfamily of proteins belonging to
the humoral arm of innate immunity and including the
classical short pentraxins (C-reactive protein (CRP) and
serum amyloid P component in human and mice, resp.) and
long pentraxins [10, 11].
CRP, prototype of the short pentraxin family, is an acute-
phase protein in humans. It is produced in the liver in
response to inflammatory signals, predominantly IL-6, it
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Table 1: Demographic and clinical characteristics of the patients.
Treated (+Dexamethasone) Untreated (−Dexamethasone) P
No. (%) No. (%)
Gender: females 5/14 (35.7%) 9/15 (60%) 0.19a
Median (1st–3rd q) Median (1st–3rd q)
Age (months) 9 (5–14) 6 (3–18) 0.30
Weight (Kg) 7.9 (6.1–8.1) 5.6 (4.0–9.8) 0.11
CPB (minutes) 95 (83–112) 93 (81–122) 0.84
AXT (minutes) 64 (59–76) 62 (46–73) 0.49
Mechanical ventilation (hours) 16.5 (9–48) 24 (16–32) 0.26
ICU stay (days) 1 (1–3) 2 (1.5–3) 0.10
Blood loss at T5 (ml/Kg/hr) 0.8 (0.7–0.9) 0.9 (0.7–1.5) 0.38
Alveolar-arteriolar oxygen diﬀerence at T5 (mmHg) 219 (158–316) 293 (152–393) 0.58
CPB: cardiopulmonary bypass; AXT: duration of aortic clamping; ICU: intensive care unit; aChi-square test.
All P values refer to Mann-Whitney U test unless otherwise specified.
interacts with diﬀerent ligands, and it is involved in innate
resistance to diﬀerent pathogens.
Long Pentraxin PTX3 is a novel inflammatory marker,
prototype of the long pentraxin family, produced by innate
immune cells and vascular cells in response to proin-
flammatory signals [10, 12]. PTX3 is a multifunctional
protein and plays complex, nonredundant roles in vivo,
recognizing a diverse range of pathogens, modulating com-
plement activity, and facilitating pathogen recognition by
macrophages and dendritic cells (DCs). Several evidences
link PTX3 and cardiovascular diseases: PTX3 production
by smooth muscle cells stimulated by atherogenic LDL,
localization in atherosclerotic lesions, and high expression
level observed in the heart during inflammatory reactions
[13, 14]. PTX3 levels increase rapidly in patients with
acute myocardial infarction (AMI), emerging as the only
independent predictor of mortality [15]. In addition PTX3
plasma levels are elevated in patients with unstable angina
and in patients undergoing stenting, suggesting that PTX3
is a candidate for being new prognostic marker in ischemic
heart disorders [16–18]. However, beside the role of PTX3
as a cardiovascular biomarker associated with inflammatory
reactions, recent in vivo and in vitro data point to a protective
cardiovascular role of PTX3 through a regulatory role on
inflammation [19, 20]. In this respect, increased levels of
PTX3 could reflect a protective response of the host.
Soluble cytokine receptor release could represent a mech-
anism to counterbalance inflammatory responses. IL-1 is a
key cytokine in inflammation and represents an important
target of GC-mediated immunosuppressive activities. GC
suppresses IL-1 production but augments cell surface expres-
sion of IL-1 receptor (R)II with consequently enhanced
release of the soluble form of the receptor itself [21, 22]. IL-
1 RII has no signalling properties, acts as a “decoy” target
for IL-1, binding with high aﬃnity to IL-1 and preventing its
binding to the signalling IL-1RI [23].
Here we have analysed the influence of dexamethasone
prophylaxis in pediatric patients undergoing CPB on blood
levels of PTX3, IL-1 RII, and other inflammatory parameters.
2. Patients and Methods
2.1. Patients. Twenty-nine children admitted to the Car-
diovascular Surgery Unit of the G. Gaslini Institute were
enrolled in the study (Table 1). Inclusion criteria were
body weight <10Kg and type of surgery (biventricular
corrections), excluding neonates and all residual intracardiac
shunts that could prevent the analysis of pulmonary oxygen
exchanges. This study protocol has been approved by the
Ethical Committee of the G. Gaslini Institute in Genoa, Italy.
Patients were randomized into two groups: (a) +D:
14 children receiving prophylaxis with dexamethasone; (b)
−D: 15 controls. Group +D patients received two doses
of 1.5mg/Kg dexamethasone i.v. or i.m.: the first dose at
the evening before surgery, the second dose 30 minutes
before starting CPB. All patients in both groups were treated
with the same protocols for anaesthesia and extracorpo-
real perfusion. Blood samples were collected preoperatively
before steroid administration (T1), 10min after the starting
of CPB (T2), after aortic cross-clamping release (T3), at
the end of CPB (T4), and on the 1st (T5) and 2nd (T6)
postoperative day. The method used to assign interventions
to trial participants was a simple random assignment with an
allocation sequence generated by an automatic routine (with
the software SPSS), with an allocation ratio of 1 : 1. The two
patient groups were homogeneous in terms of gender, age,
and weight (Table 1).
Patient clinical evaluation included duration of CPB and
aortic declamping, duration of mechanical ventilation, dura-
tion of stay in Intensive Care Unit (ICU), and postoperative
blood loss and alveolar-arterial oxygen diﬀerences at T5
(Table 1). No relevant complications were observed in the
perioperative course.
2.2. Assays for PTX3, IL-1 RII, CRP, Fibrinogen, and PTT.
Blood samples were collected at the indicated time points
(see above) in tubes containing ethylenediaminetetraacetic
acid. Plasma was obtained by sample centrifugation and
stored at−80◦C until use. PTX3 plasma levels weremeasured
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by an in-house ELISA as previously described [24, 25].
Detection limit is 100 pg/mL and interassay variability is
8–10%. IL-1RII was measured by sandwich ELISA using
the anti-IL-1RII monoclonal antibody 8.5 and an anti-IL-
1RII polyclonal antibody, both of which were generated by
some of us [21]. The lowest detection limit of this assay was
20 pg/mL.
CRP was measured by immunoturbidimetric assay
(Roche Diagnostic S.p.AMilano, Italia). Fibrinogen and PTT
were measured by photometric and turbidimetric detection
systems (BCS-XP, Siemens Healthcare Diagnostic, Deerfield,
Ill, USA).
2.3. Statistical Analysis. Descriptive analyses were firstly per-
formed; qualitative data were reported in terms of absolute
frequencies and percentages, and quantitative data were
reported as median values with first and third quartiles (1st–
3rd q). Comparison of qualitative data between two groups
of patients (treated versus untreated) was performed by the
chi-square test; comparison of quantitative data between two
groups of patients was performed by the Mann-Whitney U
test.
The comparison of quantitative data at diﬀerent time
points was evaluated by the nonparametric analysis of vari-
ance (Friedman’s test), and the post hoc analysis was made
by the Wilcoxon test adjusted with Bonferroni’s correction.
In order to evaluate diﬀerences between quantitative
data at each time point between the two groups of
patients (treated versus untreated), the Mann-Whitney U
test adjusted with the Bonferroni’s correction was applied.
In the figure data were presented as median values with first
and third quartiles.
All the statistical tests were two sided and a P value
less than .05 was considered as statistically significant. The
software “Statistica” (StatSoft Co., Tulsa, OKla, USA) was
used for all the statistical analyses.
3. Results
3.1. Eﬀect of Dexamethasone Prophylaxis on Blood Levels of
Pentraxins (PTX3/CRP) and Other Inflammatory Parameters.
PTX3 levels were assayed in plasma samples collected at dif-
ferent times in 12 patients from group +D and 12 from group
−D. When compared with baseline levels observed at T1
(median 5.87 ng/mL), PTX3 concentration in patients from
group −D increased significantly during CPB at T3 (median
12.39 ng/mL, P = 0.0184), T4 (median 21.76 ng/mL, P =
0.0110), T5 (median 104.61 ng/mL, P = 0.0110), and T6
(median 42.44 ng/mL, P = 0.0110). PTX3 plasma levels at
T2 did not diﬀer significantly from those detected at T1
(Figure 1(a)).
Plasma levels of PTX3 in group +D patients, when com-
pared with plasma concentrations detected in T1 (9.72 ng/
mL), increased significantly at T2 (median 66.37 ng/mL, P =
0.0235), T3 (96.04 ng/mL, P = 0.0110), T4 (181.42 ng/mL,
P = 0.0110), and T5 (172.7 ng/mL, P = 0.0110). PTX3 levels
at T6 in group +D patients did not significantly diﬀer from
those detected at T1 (Figure 1(a)).
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Figure 1: Plasma levels of PTX3 (a) and soluble IL1 receptor
II (b) in pediatric patients undergoing CPB, either treated or
untreated with dexamethasone. Values are expressed as medians
and 1st and 3rd quartile. Time of blood sampling: T1, preoperative,
before steroid administration; T2, 10min after CPB; T3, after aortic
declamping; T4, at the end of CPB; T5, 1st postoperative day; T6,
2nd postoperative day.∗∗∗P < 0.001.
Plasma concentrations of PTX3 during CPB in +D
patients were significantly higher than those detected in −D
patients at T2, T3, and T4 (P = 0.0002), but did not diﬀer at
T1, T5, and T6 (Figure 1(a)).
Plasma levels of soluble IL-1RII were assayed during
CPB in 12 −D and 8 +D patients (Figure 1(b)). Increased
IL-1RII levels were detected in both groups at T5 and T6
(T5: 6.35 ng/mL, T6: 6.47 ng/mL median values in −D; T5:
11.72 ng/mL, T6: 12.9 ng/mL median values in +D) in com-
parison with baseline values (4.27 ng/mL and 4.38 ng/mL
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Figure 2: Plasma levels of CRP (a) and fibrinogen (b), and PTT values (c) in children undergoing CPB, either treated or untreated with
dexamethasone. Values are expressed as medians and 1st and 3rd quartile. Time points are defined in Figure 1. ∗∗∗P < 0.001; ∗∗P < 0.01;
∗P < 0.05.
median values in −D and +D, resp.) (Figure 1(b)). These
results showed a trend towards, but did not reach, statistical
significance possibly due to the limited sample analyzed.
Similarly, IL-1RII levels at T5 and T6 in group +D, although
higher, did not significantly diﬀer from those observed in
group −D at the same time points.
Short pentraxin CRP plasma levels were assayed during
CPB in 14−D and 13 +D patients. As shown in Figure 2(a), a
significant increase of CRP was detected both in −D and +D
patients at T5 (−D 7.8mg/dL, +D 1.3mg/dL median values;
P = 0.0049 and P = 0.0073, resp.) and T6 (−D 11mg/dL,
+D 3.1mg/dL median values; P = 0.0049 and P = 0.0073,
resp.) as compared to the baseline levels (0.4mg/dL median
value for both groups). It is of note that CRP values in −D
patients at T5 and T6 were significantly higher than those
detected in +D patients (T5 P = 0.0002; T6 P = 0.0034).
Finally, fibrinogen plasma concentrations and PTT were
tested at T1, T4, T5, and T6 in 11 patients. Consistent
with the CRP results, significantly decreased fibrinogen
concentrations (−D 460mg/dL, +D 284mg/dL; P = 0.004)
and PTT (−D 34.3 sec, +D 27.6 sec; P = 0.025) were detected
in +D versus−D patients at T5 (Figures 2(b) and 2(c), resp.).
4. Discussion
This study demonstrates for the first time that dexam-
ethasone prophylaxis in pediatric patients undergoing car-
diopulmonary bypass for heart surgery is associated with
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significantly increased plasma levels of the long pentraxin
PTX3 at diﬀerent time points. This result was obtained
from the study of a homogenous patient group selected in
the frame of a clinical trial. Evidence for the potent anti-
inflammatory eﬀects of dexamethasone was obtained from
laboratory studies; patient clinical evaluation pointed to a
beneficial eﬀect of steroid prophylaxis on the postoperative
outcome which however did not reach statistical significance.
Steroid prophylaxis during CPB on inflammation and
clinical postoperative recovery has been investigated in
diﬀerent studies with opposite results, that is, beneficial
versus irrelevant eﬀects. These discrepancies may be related
to the age of patients enrolled in these studies and to dosage,
timing and the type of steroid administered [3–9].
PTX3 was found to be increased also in control patients
not receiving dexamethasone. However, (i) PTX3 levels
were significantly higher in dexamethasone-treated versus
dexamethasone-untreated patients and (ii) increased and
returned to baseline values earlier in the former than in latter
group.
Plasma concentrations of short pentraxin CRP, which
represents a reliable inflammatory marker, were similar in
+D-treated versus −D patients until T4, when PTX3 levels
were significantly higher in the former than the latter group.
CRP plasma levels were increased in −D versus +D patients
at T5 and T6, when PTX3 levels were not statistically
diﬀerent in the two groups. These latter results may be
explained on the ground of the potent anti-inflammatory
activity of dexamethasone. Superimposable behaviour was
observed for fibrinogen plasma levels and PTT, both of which
were significantly higher in −D versus +D patients at T5
only.
IL1-RII is an IL-1 decoy receptor endowed with anti-
inflammatory activity. We found increased serum levels of
IL-1RII in glucocorticoid-treated patients which however did
not reach statistical significance.
Dexamethasone was previously found to inhibit the
lipopolysaccharide-induced PTX3 production in myeloid
DC [26]. In contrast, in fibroblasts and endothelial cells,
dexamethasone alone induced and, under inflammatory
conditions, enhanced PTX3 production. The divergent eﬀect
of glucocorticoid on PTX3 regulation is likely due to
diﬀerences in the functionality of their receptor in diﬀerent
cell populations. Glucocorticoid receptor could act as ligand-
dependent transcription factor through direct DNA binding
(dimerization-dependent), or as gene transcription repressor
through protein-protein interference with the action of
another signalling pathway (dimerization-independent) [27,
28]. In nonhaematopoietic cells the stimulation of PTX3
gene expression and production is dimerization dependent;
on the contrary, suppression of PTX3 production in cells
of haematopoietic origin is dimerization independent and
mediated by interference with other signalling pathways,
most likely the NF-kB and AP-1 pathways [26]. Thus the
increased PTX3 levels observed in the present investigation
could be in part due to the regulatory role exerted by
glucocorticoids on PTX3 expression.
A further attractive candidate is IL-10, an anti-
inflammatory cytokine that is known to increase in sera
from patients receiving methylprednisolone during car-
diopulmonary bypass [5]. IL-10 is a mild inducer of PTX3
expression in DC and monocytes [29]. In this respect, we
have observed that plasma IL-10 concentrations, tested at T3
and T4, were augmented in some +D versus −D patients
(data not shown). These preliminary findings warrant
further investigation.
Recent observations in vivo in the mouse demonstrate
that PTX3 canmodulate neutrophils recruitment at inflamed
site through the interaction with P-selectin, a molecule
involved in the early steps of leukocyte recruitment [30]
These data provide a first description of the mechanisms
underlining the regulatory role on inflammation exerted by
PTX3.
In conclusion, in this study, dexamethasone prophylaxis
did not significantly aﬀect the postoperative course although
significantly inhibited the inflammatory response. In partic-
ular, PTX3 increase in patients treated with dexamethasone
may be involved in downregulation of inflammatory param-
eters and represent a mechanism of vascular endothelium
protection.
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